Combination Hormone/Vaccine Therapy May Benefit Prostate Cancer Patients
A new study provides evidence that a prostate cancer vaccine combined with hormone-deprivation therapy can help patients with recurrent prostate cancer. The results of this clinical trial, led by scientists at the National Cancer Institute (NCI), appear in the August Journal of Urology.
The phase II trial was designed to treat patients with nonmetastatic prostate cancer who were experiencing rising levels of prostate-specific antigen (PSA), an indicator of disease recurrence. Prostate cancer often progresses several years after treatment with hormone-deprivation (antiandrogen) therapy.
This is the first study to combine antiandrogen therapy and a cancer vaccine for treating prostate cancer, and also the first randomized clinical trial in this population of prostate cancer patients. Read more
Nanotech and Proteomics Fuel Expanded Communication
As the recent special issue of the NCI Cancer Bulletin on communication highlighted, NCI and the cancer community have embraced technology as a means of facilitating communication among and between the cancer community and the public.
The complexity and pace of research today demand that researchers communicate more often and more effectively, and have access to shared resources that promote collaboration. Although many researchers in certain fields discuss their work when the opportunities arise, we can no longer solely rely on research conferences as a means of forging relationships, and learning about new science and new opportunities. This is especially true if we are to fully realize the inherent advantages of team science and inter- and cross-disciplinary collaboration. Read more